Effects of Aerosol Colistin Treatment of Pneumonia Caused by Multi-drug Resistant Acinetobacter baumannii.
- Author:
Hye Sook CHOI
1
;
Yeon Hee HWANG
;
Myung Jae PARK
;
Hong Mo KANG
Author Information
- Publication Type:Comparative Study ; Original Article
- Keywords: Acinetobacter baumannii; Colistin neubulizer; Pneumonia
- MeSH: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Administration, Intravenous; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoconstriction; Colistin; Gram-Negative Bacteria; Humans; Intensive Care Units; Medical Records; Pneumonia; Retrospective Studies; Stress, Psychological
- From:Tuberculosis and Respiratory Diseases 2008;64(1):8-14
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Acinetobacter infections are difficult to treat as they often exhibit multiple resistance to the antibiotics that are currently available for the treatment of pneumonia. Colistin is active against gram-negative bacteria, including the multiple drug resistant (MDR) Acinetobacter species. However, intravenous administration of colistin was abandoned because of its nephrotoxicity and neurotoxicity. The aims of this study were to examine the efficacy and safety of colistin administered by aerosol in the treatment of pneumonia caused by MDR Acinetobacter baumannii. METHODS: We retrospectively reviewed the medical records of patients admitted to the intensive care unit (ICU) from Dec. 2006 to Aug. 2007 who had been diagnosed as suffering from pneumonia due to MDR Acinetobacter baumannii and had been treated with nebulized colistin. RESULTS: 31 patients received aerosolized colistin. The average duration of the treatment was 14+/-7 days and the daily dose of ranged from 225 mg to 300 mg. All patients received concomitant intravenous antimicrobial agents. The average length of the stay in the ICU was 34+/-21 days and in the hospital 58+/-52 days. The overall microbiological eradication was observed in 25 patients (80.6%). 14 of these (56%) were cured, and 11 (44%) were infected with other microorganisms. The overall crude mortality of the ICU was 48%. Nephrotoxicity and significant bronchial constriction did not occur in any patient during neublized colistin treatment. CONCLUSION: Nebulized colistin may be a safe and effective option in the treatment of pneumonia due to MDR Acinetobacter baumannii. Its role in therapy warrants further investigation in comparative studies.
